How big is the Spasticity Treatment Market?

The Spasticity Treatment Market size is expected to reach USD 1.31 billion in 2024 and grow at a CAGR of 8.02% to reach USD 2.11 billion by 2029. Read More

What is the current Spasticity Treatment Market size?

In 2024, the Spasticity Treatment Market size is expected to reach USD 1.31 billion. Read More

Who are the key players in Spasticity Treatment Market?

Medtronic Plc, Piramal Enterprises Ltd, Allergan plc, Ipsen and F. Hoffmann-La Roche Ltd are the major companies operating in the Spasticity Treatment Market. Read More

Which is the fastest growing region in Spasticity Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Spasticity Treatment Market?

In 2024, the North America accounts for the largest market share in Spasticity Treatment Market. Read More

What years does this Spasticity Treatment Market cover, and what was the market size in 2023?

In 2023, the Spasticity Treatment Market size was estimated at USD 1.20 billion. The report covers the Spasticity Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Spasticity Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Spasticity Treatment Market Share

Statistics for the 2023 & 2024 Spasticity Treatment market share, created by Mordor Intelligence™ Industry Reports. Spasticity Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Spasticity Treatment Industry

The spasticity treatment market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominating the market are developing new products to address unmet challenges in the market. For instance, in October 2023, Medtronic received US Food and Drug Administration (FDA) approval for its next-generation SynchroMed III intrathecal drug delivery system for patients with chronic pain, cancer pain, and severe spasticity. Some companies dominating the market are Medtronic PLC, Piramal Enterprises Ltd, Allergan PLC, Ipsen, and F. Hoffmann-La Roche Ltd.